Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
July 2024
Association of sustained lupus low disease activity state with improved outcomes in systemic lupus erythematosus: a multinational prospective cohort study
Lancet Rheumatol 2024:S2665-9913(24)00121-8 DOI 10.1016/S2665-9913(24)00121-8 Epub ahead of print
This study by Golder, et al. showed a significant protective association of lupus low disease activity state (LLDAS) and remission against damage accrual and flare. The authors also found a threshold of 3 months sustained LLDAS or remission, and that 3 months of sustained LLDAS are attainable in the setting of a 6–12-month clinical trial.
Keywords:
April 2024
Smith-specific regulatory T cells halt the progression of lupus nephritis
Nat Commun. 2024 Feb 6;15(1):899 DOI: 10.1038/s41467-024-45056-x
Compared with polyclonal mock-transduced regulatory T cells (Tregs), Smith(Sm)-Tregs potently suppress Sm-specific pro-inflammatory responses in vitro and suppress disease progression in a humanised mouse model of lupus nephritis.
Keywords:
March 2024
Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: A multinational observational cohort study
Ann Rheum Dis. 2024 Feb 29:ard-2023-225369 doi: 10.1136/ard-2023-225369 Epub ahead of print
Flare risk did not increase following glucocorticoid tapering in modified serologically active clinically quiescent patients with SLE. They also found that antimalarial use was associated with decreased flare risk.